Member Info for Aqc888

Good old cancel culture. The end of debate. An opposing view must be cancelled for “deliberate intention of disruption”.

$20 for a six-pack of, 5 oz. bags…

Teks portfolio just falls apart quicker than a cheap suit, the more you look into it the worse it gets!

https://thespoon.tech/microsalt-reformulates-salt-so-you-use-less-of-it/

Regarding microsalt introduced in supermarkets. I think from memory around 75% of new listings on supermarket shelves don’t survive a year. Microsalt will have the ability to pay the supermarket’s to get premium position on shelves and conduct various intensive advertising. However the odds are stacked against them. The posts here giving the sales from the first month as evidence of microsalts future trajectory are not to be taken seriously.

Tek has a very small concentrated portfolio. The discount to nav explains all you need to know about the quality of its investments. Call me what you like, but it’s weak.

Read this from teks own introduction;
This statement should sound alarm bells regarding their credibility

“Tekcapital have developed a unique algorithm called Innovation
Discovery Network (IDN), which is a specialist search engine platform
capable of locating cutting edge technology and Intellectual Property (IP)”

Read this which should add some reality. Even if fully autonomous cars do make the mainstream in contradiction to the ft article. What are the chances the likes of Tesla /Google are going to outsource the most important part (safety) to a third party? The journey to fully autonomous is taking much longer than expected. Think teks investment will last the next 5-10yr without running out of money?

https://www.ft.com/content/46ff4fe4-0ae6-4f68-902c-3fd14d294d72

Genuine answer, tek has an incredibly weak portfolio in my opinion. The more I look into it the weaker it appears and the superiority of frontier ip and Augmentum fintech become apparent. I feel that tek is deserving of its large discount to nav and many investors here would benefit from looking at similar more diversified, better companies in the same field, with vastly superior prospects.

You all realise that when the microsalt products are put in supermarkets there will be a huge unsustainable effort to get high sales in that initial period to secure their ‘shelf space’.

https://www.ft.com/content/46ff4fe4-0ae6-4f68-902c-3fd14d294d72

Read this which might make some of you think twice about teks biggest holding.

Tek is relying on some big behavioural changes. In regards to completely driverless autonomous cars - which the ft article from my last post doubts will happen.

The eyewear business… Google glasses failed recently… if Google can’t crack it I doubt this little outfit will.

We’ve had low salt products for ages which have never caught on in a big way, although this would be the safest investment- however turnover is pathetic.

No wonder they could only raised funds at 25p when the nav is a supposedly 45p. Frontier ip with a far better portfolio has a nav of around the same as the share price

very speculative technology tek has its biggest bet on. Read this Financial Times article which applies to the level 4 business model Guident is aiming for. Guident is very much the ‘moonshot’ solution while the Financial Times speculates the evolutionary approach will prevail.

https://www.ft.com/content/46ff4fe4-0ae6-4f68-902c-3fd14d294d72

You’re betting on a solution to a new technology that hasn’t even been through trials. New technologies evolve rapidly and unpredictably with an array of new solutions to new problems. Tek is beyond a “moonshot” it’s more of a “Pluto shot”. Look at the portfolio of sensible investments in Augmentum and Frontier IP. Then compare them with the Tek “Pluto shot” portfolio.

Simon Thompson has a long track record of getting it wrong with these venture capital picks. Arix bioscience down 50%. Allied minds down 100%. BATM down 50%. He’s got it wrong again here. The discounts to nav are there for a reason. NOT a bargain. 20p and it’s worth taking a risk. 25p is a joke.

That £1.2m order was what you were waiting for. It’s happened. Kromek style.

So many of Frontiers investments seem to be spot on for todays market place. From software that increases efficiency for logistics companies reducing fuel. To covid vaccines and robots to reduce farm labour in short supply. Plusiv - which reduces electricity consumption. A fantastic range of products maturing for todays world

Each robot has x4 arms however. So x16kg/hour working 24hrs a day and with only the best fruit picked. The robot also remembers where and when to return to almost ready fruit. The quality of the berries is also better than picked by hand as the robot is more delicate and precise

You’d be better off at the casino on red and black. At least that way you won’t be giving your capital interest free for 1-3years. Essentially nothing the board can be trusted. Don’t you think it’s odd that they have this ground breaking biological pathogen detector technology, yet there is no government or media interest? A bit odd if there wasn’t the track record of Kromek. With the track record of Kromek it’s completely believable. Who knows. But past performance is probably a good indication of what the future holds - and that future is a golden turd freshly laid by the CEO who is adamant it’s not a turd but a superb golden egg

Just been tipped yet again by Simon Thompson

The board say all the profit is coming in the second half! Nothing to worry about here! Haha. It’s customary for the board to blame something out of their control for dire performance. So I’d imagine the Russian situation will be used in some way…” couldn’t sell any biological pathogen detectors since defence departments were too busy dealing with Russia” - some nonsense like that will be on the cards..

They couldn’t sell any liquid bomb detectors. Couldn’t sell many CZT detectors - and when they did they didn’t get paid for a £10m sale to China. No covid detectors were sold and they’re having trouble shifting the wide spectrum detector. However they do seem rather successful at selling fundraisings to shareholders every few years, seems to be their main source of income and a lot easier than selling products!

I first bought in at below 10p, my highest point was buying at 17p. I sold half before the Russian invasion for a profit and have seen my remaining stake go to a loss from a over 100% gain at one point. I still own some Kromek. Kromek is an interesting share, no doubt about it, a lot of unknowns and it’s a bit of a riddle. I’ve posted plenty of positive Kromek posts in the past and would like to see some counter arguments to my negative posts currently. However there don’t seem many counter arguments based on any facts. The situation seems to be dire. There seems little positive news to come, wild swings could continue. Would be interested to see some positive posts on why the biological pathogen detector or wider business is sound. But as long term watchers like skid or QP, I’m increasingly starting to realise Kromek is continuing a long term trend of failure. I’m pretty confident of my position on Kromek and I know enough about it to react quickly if they do successfully pull out a wild card. We could see some more wild swings down and up. Vascular, why don’t you explain all the failures, especially regarding the biological pathogen detector. It’s not that the failure to get sales on time that particularly irritates me - it’s the repeated statements by the company that are proved to be extremely dodgy over time that irritate me. Personally I now see the opaqueness management create to be a strategy to keep shareholders continually holding on a bit longer and they’ve got a very weak hand they are reluctant to play. But I’d like to be enlightened with a different view

Bit worrying they didn’t announce the details of the accreditation when they said that they would… Bit worrying there’s no details of the trial working by the trial partners… Bit worrying the world media haven’t been interested in Kromeks work and scientists in the field liken it to finding a needle in a haystack… bit worrying the covid specific sales which were due end of December never materialised… bit worrying despite all Kromeks claims and the collapse of Kromeks share price that no directors are interested in buying any shares no matter how low the sp goes…

At the last fundraising they said they needed the financial stability of £13m to help win large government orders. Yet 1year later they are fast approaching broke again and back to square one with a pathetic £1.7m order at the deadline of April.

So the £13m quid which was supposed to “ commercialise its bio-security and pathogen detector, as well as allowing it to ramp up its commercialisation rate.” and to “ to expand sales and marketing for the group’s nuclear detection and medical imaging activities, and to strengthen the balance sheet, giving it flexibility to address and capitalise on current and emerging opportunities.” Was nonsense.

Where are all these expanded sales? Interim results absolutely terrible. Without the US payroll covid refund
They would have been even worse than terrible.

What they were really trying to say in Feb 2021 was “£13m to allow us to play around in our labs a bit longer so we don’t need to worry about the real world problems of selling our stuff. Because selling stuff isn’t as exciting as trying to invent stuff, and we’d really like to continue our university days of state funding our research. But unfortunately we’ve chosen the commercial path and constant fundraisings is the best of both worlds. No need to get our hands dirty with sales etc and play around loads. Then if one day we invent something people actually want to buy hopefully we’ll be rich. But in the meantime the £350k+ salary these mugs allow us to earn will do very nicely, we’ve just got to feed those greedy shareholders who expect profits some silly science they don’t understand and keep it up year after year.”